{
    "id": 10676,
    "fullName": "TPM3 - ROS1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TPM3-ROS1 results from the fusion of TPM3 and ROS1, and leads to cell transformation in culture and tumorigenesis in animal models (PMID: 22327623). TPM3-ROS1 has been identified in lung cancer (PMID: 25667280).",
            "references": [
                {
                    "id": 3475,
                    "pubMedId": 22327623,
                    "title": "RET, ROS1 and ALK fusions in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22327623"
                },
                {
                    "id": 3397,
                    "pubMedId": 25667280,
                    "title": "Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25667280"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7170,
        "geneSymbol": "TPM3",
        "terms": [
            "TPM3",
            "CAPM1",
            "CFTD",
            "HEL-189",
            "HEL-S-82p",
            "hscp30",
            "NEM1",
            "OK/SW-cl.5",
            "TM-5",
            "TM3",
            "TM30",
            "TM30nm",
            "TM5",
            "TPM3nu",
            "TPMsk3",
            "TRK"
        ]
    },
    "variant": "TPM3 - ROS1",
    "createDate": "08/16/2015",
    "updateDate": "03/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 6098,
                "geneSymbol": "ROS1",
                "terms": [
                    "ROS1",
                    "c-ros-1",
                    "MCF3",
                    "ROS"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) demonstrated superior activity against transformed cells expressing TPM3-ROS1 in culture compared to other inhibitors targeting Ros1 (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1319).",
            "molecularProfile": {
                "id": 10680,
                "profileName": "TPM3 - ROS1"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14995,
                    "pubMedId": null,
                    "title": "Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) demonstrated superior activity against transformed cells expressing ROS1 L2026M in the context of TPM3-ROS1 in culture compared to other inhibitors targeting Ros1 (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1319).",
            "molecularProfile": {
                "id": 32097,
                "profileName": "TPM3 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14995,
                    "pubMedId": null,
                    "title": "Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) demonstrated superior activity against transformed cells expressing ROS1 G2032R in the context of TPM3-ROS1 in culture compared to other inhibitors targeting Ros1 (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1319).",
            "molecularProfile": {
                "id": 32106,
                "profileName": "TPM3 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14995,
                    "pubMedId": null,
                    "title": "Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10680,
            "profileName": "TPM3 - ROS1",
            "profileTreatmentApproaches": [
                {
                    "id": 16894,
                    "name": "ROS1 Inhibitor",
                    "profileName": "TPM3 - ROS1"
                }
            ]
        },
        {
            "id": 32097,
            "profileName": "TPM3 - ROS1 ROS1 L2026M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32106,
            "profileName": "TPM3 - ROS1 ROS1 G2032R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}